Lung cancer incidence rates in the United States have undergone a significant transformation over the last several decades, ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma ...
Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...
Kyle Donahue, who was given months to live after receiving a diagnosis of glioblastoma in 2021, enrolled in a clinical trial ...
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...
The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...
Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...
Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% reduction in progression or death. The MajesTEC-9 trial highlights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback